New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4): Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 9, 2026
March 9, 2026
887fce8a-3c4a-41cd-9f2c-8e1e159e3547
Related Documents
Development of Non-Opioid Analgesics for Chronic Pain
Guidance DocumentMay 13, 2026Center for Drug Evaluation and Research
Development of Non-Opioid Analgesics for Acute Pain
Guidance DocumentMay 13, 2026Center for Drug Evaluation and Research
Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.